Oculis secures worldwide rights to Accure Therapeutics’ Privosegtor and ACT-02 in a $3.8M upfront deal plus 2.05M shares.
Oculis Holding (OCS) has agreed to acquire worldwide rights to Privosegtor and ACT-02 from Accure Therapeutics for $3.8M in cash and up to 2.05M ordinary shares. The deal was announced Monday and marks a strategic expansion for Oculis in therapeutic assets.
The acquisition includes an upfront payment and equity, with no prior public valuation disclosed for the assets. Privosegtor and ACT-02 are part of Accure’s pipeline, though specific development stages or prior financials were not detailed in the release.
No immediate market reaction was reported following the announcement.